FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $135,953 | -58.8% | 64,129 | -7.4% | 0.00% | – |
| Q2 2023 | $329,734 | +10.5% | 69,272 | +32.4% | 0.00% | – |
| Q1 2023 | $298,317 | -45.1% | 52,335 | -2.8% | 0.00% | -100.0% |
| Q4 2022 | $543,515 | -43.1% | 53,865 | +26.3% | 0.00% | -50.0% |
| Q3 2022 | $956,000 | -17.0% | 42,655 | -8.2% | 0.00% | 0.0% |
| Q2 2022 | $1,152,000 | -34.1% | 46,476 | +3.1% | 0.00% | 0.0% |
| Q1 2022 | $1,747,000 | -24.7% | 45,072 | +13.7% | 0.00% | -33.3% |
| Q4 2021 | $2,320,000 | +52.2% | 39,642 | +54.2% | 0.00% | +50.0% |
| Q3 2021 | $1,524,000 | +47.7% | 25,710 | +116.2% | 0.00% | 0.0% |
| Q2 2021 | $1,032,000 | +43.9% | 11,890 | +36.7% | 0.00% | +100.0% |
| Q1 2021 | $717,000 | +3.2% | 8,696 | +13.8% | 0.00% | 0.0% |
| Q4 2020 | $695,000 | +118.6% | 7,639 | -4.1% | 0.00% | 0.0% |
| Q3 2020 | $318,000 | +22.8% | 7,968 | +5.5% | 0.00% | 0.0% |
| Q2 2020 | $259,000 | – | 7,550 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |